NCT07218796 - Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

October 28, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

May 31, 2031

Conditions

CataractGlaucomaOcular Hypertension

Interventions

DRUG

Bimatoprost Implant System

Bimatoprost Implant System used in combination with the SpyGlass IOL

DEVICE

SpyGlass IOL

SpyGlass Intraocular Lens

DRUG

Timolol Maleate Ophthalmic Solution, 0.5%

Timolol Maleate Ophthalmic Solution, 0.5% BID

DEVICE

Commercial IOL

Commercially Available Aspheric Monofocal Non-Yellow Chromophore Intraocular Lens

Trial Locations (1)

RECRUITING

R and R Eye Research, LLC, San Antonio

All Listed Sponsors

lead

SpyGlass Pharma, Inc.

INDUSTRY